Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation.
Gaetano M De Ferrari, Veronica Dusi, Carla Spazzolini, J Martijn Bos, Dominic J Abrams, Charles I Berul, Lia Crotti, Andrew M Davis, Michael Eldar, Maria Kharlap, Asaad Khoury, Andrew D Krahn, Antoine Leenhardt, Christopher R Moir, Attilio Odero, Louise Olde Nordkamp, Thomas Paul, Ferran Rosés I Noguer, Maria Shkolnikova, Jan Till Show all
Circulation | Published : 2015
BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder causing life-threatening arrhythmias whenever sympathetic activity increases. β-Βlockers are the mainstay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used but often cause multiple shocks. Preliminary results with flecainide appear encouraging. We proposed left cardiac sympathetic denervation (LCSD) as useful additional therapy, but evidence remains anecdotal. METHODS AND RESULTS: We report 63 patients with CPVT who underwent LCSD as secondary (n=54) or primary (n=9) prevention. The median post-LCSD follow-up was 37 months. The 9 asymptomatic patients remained free..View full abstract